OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
Insurty gets ready to meet FDA’s requirement that regulatory submissions be in eCTD format.
FDA's announcement in December 2007 that it would only accept electronic regulatory submissions in eCTD format starting January 1st was no cause for concern for Boehringer Ingelheim. That's because by then the Ingelheim, Germany-based pharmaceutical company could compile a compliant eCTD (electronic common technical document) submission.
The journey to compliance began in early 2007 when the pharmaceutical goliath—which operates in 47 countries and employs a little over 38,000 people—sized up its best options. Those included, it determined, outsourcing to a solution's provider with a track record of long-term stability and using software as a service (SaaS).
Drag and drop capabilities allow users to easily add study files to their U.S. eCTD, which can be turned into an EU submission in a few steps.
Image Solutions, Inc. (ISI; Whippany, NJ, and Eschborn, Germany), a company Boehringer Ingelheim worked with since 2003, met the selection criteria along with its eCTDXPress. The application from ISI creates, manages, and reviews eCTDs and comes in different configurations, including as a desktop solution and a SaaS enterprise solution.
"Software as a service was an attractive option for us to have a validated eCTD tool available within a short time without taking away resources from other ongoing and important projects in R&D and related to submissions," said Dr. Hanns-Georg Leimer, head of Boehringer Ingelheim's Global Document Management Solution Center. In the end, the option proved as good a fit as the software.
First, the company met its own eCTD-ready deadline of less than a year. Second, eCTDXpress easily integrated with their document management system, Documentum from EMC (Hopkinton, MA). Smooth software integration was no coincidence, as eCTDXPress is compatible with Documentum and other document management systems, like LiveLink from OpenText (Ontario, Canada).
Going the SaaS route also allowed Boehringer Ingelheim to cut internal support costs by 40%, according to Gilbert Kampfner, managing director of ISI Europe. "In comparison to buying normal software, you have a fairly low start-up cost," he told Applied Clinical Trials, "for every dollar you spend buying the software, you have to spend two on implementation and validation."
An additional benefit eCTDXPress as an SaaS solution provides Boehringer Ingelheim is freedom. As Kampfner explained, "SaaS puts the shoe on the other foot"—the vendor's foot. That means it is ISI's responsibility to upgrade the software (including when FDA updates the submission form), provide end user support, fix bugs, and install patches. This lets the pharma company focus its attention on what it does best: research and development.
Since first implementing ISI software five years ago (ISIToolBox, DocComposer, and CRFTrack), Boehringer Ingelheim estimates that it has shaved at least two weeks off the submissions process.—Kerri Nelen